From July 28 to August 1, 2024, the 76th ADLM was successfully held at the McCormick Place Convention Center in Chicago, USA.

The name ADLM may sound a little strange, but the name of AACC is well-known in the IVD industry. The Annual Scientific Meeting & Clinical Lab Expo, hosted by the American Association for Clinical Chemistry (AACC), founded in 1949, was officially renamed the Annual Scientific Meeting & Clinical Lab Expo (ADLM) in 2024.

As one of the highest quality and largest annual events in the field of clinical testing at home and abroad, the conference attracted more than 20,000 international medical professionals from 110 countries. The conference also displayed a large number of the latest clinical laboratory testing technology equipment and in vitro diagnostic products, sharing the industry's cutting-edge technologies, important research and development trends.

BioHermes closely follows the cutting-edge direction of the industry and continuously strengthens its innovative research and development layout, bringing its independently innovative and developed Botangping® full range of glycated hemoglobin testing products, new immunofluorescence platform products and other exciting appearances to this exhibition.

BioHermes brought a variety of core glycated hemoglobin testing products in the field of diabetes management, including A1c EZ 2.0, GlucoA1c, A1cChek Pro, A1cChek Express, Limpid, BH60 (HPLC), etc. BioHermes' glycated hemoglobin testing products have made a wonderful appearance at this exhibition. BioHermes' glycated hemoglobin testing products include more than 100 domestic and foreign patents, including more than 50 invention patents and more than 20 overseas patents. They have the comprehensive advantages of more efficient testing speed, more accurate test results, more convenient and simple operation, and more comprehensive application scenario coverage. They can provide more accurately matched products for the diverse application needs of global customers, and won wide acclaim from international customers and partners at the exhibition.

In addition, BioHermes has continued to deepen its presence in the field of in vitro diagnostics, actively deployed in the field of immunofluorescence testing, and launched a variety of testing instruments and test projects. At this exhibition, BioHermes showed its new immunofluorescence platform products to partners at home and abroad - the BF-100 portable multifunctional immunofluorescence analyzer and the BF-300 multi-channel immunofluorescence analyzer. BioHermes' immunofluorescence series products fully support dry immunochromatography (immunofluorescence, time-resolved and colloidal gold) and dry photochemical detection systems, with a more friendly human-computer interaction design, a more flexible cascade method, and more comprehensive scene coverage. It can be used in medical institutions, testing departments and other scenarios, providing more efficient, accurate and convenient solutions for clinical diagnosis and treatment. The immunofluorescence series of products has also gained customer attention and recognition with its advantageous characteristics.

As the 2024 ADML exhibition came to a successful conclusion, we are deeply honored to share our innovative achievements with our colleagues in the industry. As a leading company in the field of in vitro testing (IVD), we have always been committed to continuous innovation and technological breakthroughs. We firmly believe that through continuous research and development and improvement, BioHermes will bring faster, more convenient, more accurate and more affordable products to meet the growing market demand, and provide better product solutions for global partners. We look forward to working hand in hand with all partners to deepen cooperation and realize the beautiful vision of win-win.